Medtronic to Acquire SPR Therapeutics for $650 Million to Expand Minimally Invasive Chronic Pain Solutions

Financial and Transaction Details:

• Total Acquisition Amount: Medtronic agrees to pay approximately US$650 million in upfront cash.

• Transaction Object: Purchase of all non-circulating equity held by SPR Therapeutics.

• Closing Time: The transaction is expected to be completed in the first half of Medtronic's fiscal year 2027 (Medtronic's fiscal year 2027 officially began on April 25, 2026). Prior to the final closing of the transaction, both companies will continue to operate as independent entities.

Domenico De Paolis, interim president of the Neuromodulation division, stated: "Serving patients is our primary mission. The addition of temporary peripheral nerve stimulation helps expand access to neuromodulation through minimally invasive therapies, supporting patients at more stages of their chronic pain journey."

Industry Trends:

• The Peripheral Nerve Stimulation (PNS) sector is becoming a strategic high ground contested by major medical giants. Boston Scientific completed the acquisition of another PNS technology developer, Nalu Medical, for $600 million. Nalu Medical utilizes long-term, minimally invasive permanently implantable micro pulse generators, wirelessly powered by external patches and controlled via a mobile app, precisely targeting chronic pain patients with high compliance who require long-term neuromodulation.

The core product of SPR Therapeutics is the Sprint peripheral nerve system. With its innovative "surgery-free, implant-free" design, the system achieves pure physical pain relief without incisions or drugs. At the heart of the system is a percutaneously delivered micro-fine wire that provides precise targeting. A short clinical treatment course of just 60 days allows it to seamlessly integrate into existing standard clinical workflows. Without leaving any permanent implants in the body, the system opens up a new pathway for earlier minimally invasive intervention for patients with chronic pain.

In terms of structural design, it is mainly composed of the following four core components.

• Percutaneous Microlead —— Core Implant Contact

  Under ultrasound or imaging guidance, the doctor temporarily and precisely places this lead in the muscle tissue near the target peripheral nerve. Its spiral design ensures excellent stability within the body, making it resistant to displacement during the patient's daily activities.

• External Pulse Generator – Power and Control Brain

  The Sprint system is temporary (a 60-day course), with its "battery and chip" attached directly to the patient's skin surface (secured via a patch). It is responsible for emitting weak electrical pulses, which are transmitted to the nerves through the aforementioned leads.

• Smart Handheld Remote Control/Mobile Application —— Terminal Adjustment

  Patients can safely and independently adjust the intensity and mode of electrical stimulation based on their real-time pain sensations, achieving personalized pain management.

• Specialized Interventional Delivery Tools —— Clinical Surgical Consumables

  In the standard clinical workflow of outpatient or day surgery, doctors can quickly and accurately place leads in a minimally invasive manner, with no incision required and minimal trauma throughout the procedure.

Currently FDA approved for the following indications

• Chronic intractable pain (up to 60 days), postoperative acute pain, post-traumatic acute pain, and postoperative traumatic pain relief.

• The coverage includes areas such as the back, limbs, head, neck, and front of the torso.

Traditional Spinal Cord Stimulation (SCS)——Using permanently implanted pulse generators and electrodes requires invasive surgery, high costs, and long-term follow-up, with indications mainly focused on "refractory" chronic pain. Compared with traditional solutions, it neither requires permanent implants nor invasive surgery, significantly reducing surgical trauma and the psychological threshold for patients.

Core Survival and Efficacy Indicators

• Effective Pain Relief:Multicenter studies show that 58%-67% of patients still experience a reduction in pain of more than 50% one year after treatment.

• Get Rid of Drug Dependence:75% of baseline opioid users achieved reduction or discontinuation, with an average morphine dose decrease of 72%.

• Functional Recovery:Approximately 71% of patients showed clear clinical improvement in daily activities and life functions.

• Serious Adverse Event:0% of major surgery-related complications such as deep infection and nerve damage.

• Mild Adverse Reactions:The incidence of local skin irritation is 8%-12% (self-resolving); the probability of minimal residual at the lead tip is 1.5%-3% (harmless material, no surgical removal required); the rate of superficial skin infection is less than 2% (manageable with routine dressing changes).

Medtronic's $650 Million Acquisition of SPR Therapeutics: A Strategic Shift in Pain Management